In:
Current Pharmaceutical Design, Bentham Science Publishers Ltd., Vol. 28, No. 31 ( 2022-09), p. 2569-2582
Abstract:
Cardiovascular disease (CVD) has become a severe threat to human beings with increasing morbidity and mortality. Isorhamnetin (Iso) shows multiple bioactivities, especially in the cardiovascular system. A literature retrieval strategy was conducted in databases of PubMed, GeenMedical, Sci-Hub, Web of Science, China National Knowledge Infrastructure (CNKI), and Baidu Scholar, with keywords defined as “Isorhamnetin”, “cardiovascular diseases”, “pharmacological effects”, “phytochemistry”, “pharmacokinetics”, “clinical application” and “toxicity”. The language is restricted to Chinese and English, and publish date ranges from January 2011 to September 2021. So far, Iso has been isolated and identified from several natural medicines, including Hippophae rhamnoides L., Ginkgo biloba L. and Typha angustifolia L., etc. The effects of Iso on CVD at least refer to such pharmacological properties as anti-atherosclerosis, reducing blood fat, anti-inflammation, antioxidation, endothelial protection, antithrombosis, antiplatelet aggregation, myocardial protection and anti-hypertension. Iso could inhibit the activities of CYPs in liver microsomes and suppress hepatocyte injury in vitro, however, no toxicity was observed in vivo. Taken together, Iso has a wide range of positive effects on CVD with safe and multiple pharmacological activities on the cardiovascular system, and may be an ideal candidate drug for the prevention and treatment of CVD and need further studies, especially on clinic use. Therefore, the present review summarizes the recent progress in phytochemistry, pharmacology, and mechanisms of action and provides a reference for future studies of Iso.
Type of Medium:
Online Resource
ISSN:
1381-6128
DOI:
10.2174/1381612828666220829113132
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2022
SSG:
15,3
